GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medicenna Therapeutics Corp (TSX:MDNA) » Definitions » Repurchase of Stock

Medicenna Therapeutics (TSX:MDNA) Repurchase of Stock : C$0.00 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Medicenna Therapeutics Repurchase of Stock?

Medicenna Therapeutics's Repurchase of Stock for the three months ended in Sep. 2024 was C$0.00 Mil.

Medicenna Therapeutics's Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 was C$0.00 Mil.


Medicenna Therapeutics Repurchase of Stock Historical Data

The historical data trend for Medicenna Therapeutics's Repurchase of Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medicenna Therapeutics Repurchase of Stock Chart

Medicenna Therapeutics Annual Data
Trend Dec15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Repurchase of Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Medicenna Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Repurchase of Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Medicenna Therapeutics Repurchase of Stock Calculation

A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of Stock represents the cash outflow to reacquire common stock during the period.

Repurchase of Stock for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Medicenna Therapeutics Repurchase of Stock Related Terms

Thank you for viewing the detailed overview of Medicenna Therapeutics's Repurchase of Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Medicenna Therapeutics Business Description

Traded in Other Exchanges
Address
2 Bloor Street W., 7th Floor, Toronto, ON, CAN, M4W 3E2
Medicenna Therapeutics Corp is a Canada-based immuno-oncology company. Its principal business activity is the development and commercialization of IL-2, IL-4, and IL13 Superkines and Empowered Superkines for the treatment of cancer and other diseases. Its pipeline candidates include MDNA55 for recurrent glioblastoma multiforme (rGBM), MDNA11 for Cancer immunotherapies, MDNA209 for Autoimmune Diseases, MDNA413 for Cancer immunotherapies, and MDNA132 for Solid Tumors, BiSKITs represents the novel platform comprised of Bifunctional SuperKine ImmunoTherapies.
Executives
Fahar Merchant 10% Security Holder, Director, Senior Officer
Elizabeth Williams Senior Officer
Albert George Beraldo Director
Chandra Panchal Director

Medicenna Therapeutics Headlines

No Headlines